Opioid-induced hyperalgesia and tolerance: Understanding opioid side effects

Expert Review of Clinical Pharmacology

Volumn 1, Issue 2, 2008, Pages 291-297

  Grider, Jay S ^a   Ackerman, William E ^b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b CENTRAL BAPTIST HOSPITAL   (United States)

Author keywords

Addiction; Hyperalgesia; Opioid induced pain; Pain threshold; Tolerance

Indexed keywords

ANALGESIC AGENT; CODEINE; DIZOCILPINE; FENTANYL; HYDROCODONE; HYDROMORPHONE; METHADONE; MORPHINE; MU OPIATE RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NARCOTIC ANALGESIC AGENT; OPIATE AGONIST; OPIATE ANTAGONIST; OXYCODONE; PETHIDINE; REMIFENTANIL;

ALLODYNIA; ANALGESIC ACTIVITY; CANCER PAIN; CHRONIC PAIN; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; HUMAN; HYPERALGESIA; HYPERESTHESIA; LOW DRUG DOSE; NEURALGIA; NEUROPATHIC PAIN; NOCICEPTION; NONHUMAN; OPIATE ADDICTION; PARESTHESIA; POSTOPERATIVE PAIN; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; REVIEW; SEX DIFFERENCE;

EID: 49249138902     PISSN: 17512433     EISSN: None     Source Type: Journal    
DOI: 10.1586/17512433.1.2.291     Document Type: Review

References (89)

1. Armstrong PJ, Bersten A. Normeperidine toxicity. Anesth. Analg. 65(5), 536-538 (1986).
2. Kissin I. Preemptive analgesia. Anesthesiology 93(4), 1138-1143 (2000).
3. Angst MS, Clark JD. Opioid-induced hyperalgesia: a qualitative systematic review. Anesthesiology 104(3), 570-587 (2006).
4. Deshpande A, Furlan A, Mailis-Gagnon A, Atlas S, Turk D. Opioids for chronic low-back pain. Cochrane Database Syst. Rev. 3, CD004959 (2007).
5. Chang G, Chen L, Mao J. Opioid tolerance and hyperalgesia. Med. Clin. North Am. 91(2), 199-211 (2007).
6. Simonnet G. Complexity and physiology of the analgesic effects of opioids. Rev. Med. Suisse 1(25), 1682-1695 (2005).
7. Daniels DJ, Lenard NR, Etienne CL, Law PY, Roerig SC, Portoghese PS. Opioid-induced tolerance and dependence in mice is modulated by the distance between pharmacophores in a bivalent ligand series. Proc. Natl Acad. Sci. USA 102(52), 19208-19213 (2005).
8. Gardell LP, King T, Ossipov MH et al. Opioid receptor-mediated hyperalgesia and antinociceptive tolerance induced by sustained opiate delivery. Neurosci. Lett. 396(1), 44-49 (2006).
9. Yaksh TL, Harty GJ, Onofrio BM. High dose of spinal morphine produce a nonopiate receptor-mediated hyperesthesia: clinical and theoretic implications. Anesthesiology 64(5), 590-597 (1986).
10. Mao J. Opioid-induced abnormal pain sensitivity. Curr. Pain Headache Rep. 10(1), 67-70 (2006).
11. Mao J, Price DD, Phillips LL, Lu J, Mayer DJ. Increases in protein kinase C γ-immunoreactivity in the spinal cord dorsal horn of rats with painful mononeuropathy. Neurusci. Lett. 198(2), 75-78 (1995).
12. Mao J, Price DD, Mayer DJ. Experimental mononeuropathy reduces the antinociceptive effects of morphine: implications for common intracellular mechanisms involved in morphine tolerance and neuropathic pain. Pain 61(3), 353-364 (1995).
13. Vanderah TW, Ossipov MH, Lai J, Malan TP Jr, Porreca F. Mechanisms of opioid-induced pain and antinociceptive tolerance: descending facilitation and spinal dynorphin. Pain 92(1-2), 5-9 (2001).
14. Kayan S, Woods LA, Mitchell CL. Morphine-induced hyperalgesia in rats tested on the hot plate. J. Pharmacol. Exp. Ther. 177(3), 509-513 (1971).
15. Tilson RA, Rech RH, Stolman S. Hyperalgesia during withdrawal as a means of measuring the degree of dependence in morphine dependent rats. Psychopharmacologia 28(3), 287-300 (1973).
16. Wu KM, Martin WM, Kamerling SG, Wettstein JG. Possible medullary κ-hyperalgesic mechanism. I. A new potential role for endogenous opioid peptides in pain perception. Life Sci. 33(18), 1831-1838 (1983).
17. Passik SD, Kirsh KL. Managing pain in patients with aberrant drug-taking behaviors. J. Support. Oncol. 3(1), 83-86 (2005).
18. Davis MA, Shaiova LA, Angst MS. When opioids cause pain. J. Clin. Oncol. 25(28), 4497-4498 (2007).
19. Chu LF, Clark DJ, Angst MS. Opioid tolerance and hyperalgesia in chronic pain patients after one month of oral morphine therapy: a preliminary prospective study. J. Pain 7(1), 43-48 (2006).
20. Angst MS, Koppert W, Pahl I, Clark DJ, Schmelz M. Short-term infusion of the mu-opioid agonist remifentanil in humans causes hyperalgesia during withdrawal. Pain 106(1-2), 49-57 (2003).
21. Li X, Angst MS, Clark JD. Opioid-induced hyperalgesia and incisional pain. Anesth. Analg. 93(1), 204-209 (2001).
22. Mitchell TB, White JM, Somogyi AA, Bochner F. Switching between methadone and morphine for maintenance treatment of opioid dependence: impact on pain sensitivity and mood status. Am. J. Addict. 15(4), 311-315 (2006).
23. Doverty M, Somogyi AA, White JM et al. Methadone maintenance patients are cross-tolerant to the antinociceptive effects of morphine. Pain 93(2), 155-163 (2001).
24. Doverty M, White JM, Somogyi AA, Bochner F, Ali R, Ling W. Hyperalgesic responses in methadone maintenance patients. Pain 90(1-2), 91-96 (2001).
25. Compton P, Miotto K, Elashoff D. Precipitated opioid withdrawal across acute physical dependence induction methods. Pharmacol. Biochem. Behav. 77(2), 263-268 (2004).
26. Compton P, Athanasos P, Elashoff D. Withdrawal hyperalgesia after acute opioid physical dependence in nonaddicted humans: a preliminary study. J. Pain 4(9), 511-519 (2003).
27. Compton P, Athanasos P. Chronic pain, substance abuse and addiction. Nurs. Clin. North Am. 38(3), 525-537 (2003).
28. Compton P, Estepa CA. Addiction in patients with chronic pain. Lippincotts Prim. Care Pract. 4(3), 254-272 (2000).
29. Ackerman WE 3rd. Paroxysmal opioid-induced pain and hyperalgesia. J. Ky Med. Assoc. 104(9), 419-423 (. 2006).
30. Koppert W, Schmelz M. The impact of opioid-induced hyperalgesia for postoperative pain. Best Pract. Res. Clin. Anaesthesiol. 21(1), 65-83 (2007).
31. Pogatzki-Zahn EM, Zahn PK, Brennan TJ. Postoperative pain - clinical implications of basic research. Best Pract. Res. Clin. Anaesthesiol. 21(1), 3-13 (2007).
32. Lipman JJ, Blumenkopf B. Comparison of subjective and objective analgesic effects of intravenous and intrathecal morphine in chronic pain patients by heat beam dolorimetry. Pain 39(3), 249-256 (1989).
33. Crawford MW, Hickey C, Zaarour C, Howard A, Naser B. Development of acute opioid tolerance during infusion of remifentanil for pediatric scoliosis surgery. Anesth. Analg. 102(6), 1662-1667 (2006).
34. Guignard B, Bossard AE, Coste C et al. Acute opioid tolerance: intraoperative remifentanil increases postoperative pain and morphine requirement. Anesthesiology 93(2), 409-417 (2000).
35. Chia YY, Liu K, Wang JJ, Kuo MC, Ho ST. Intraoperative high dose fentanyl induces postoperative fentanyl tolerance. Can. J. Anaesth. 46(9), 872-877 (1999).
36. Cooper DW, Lindsay SL, Ryall DM, Kokri MS, Eldabe SS, Lear GA. Does intrathecal fentanyl produce acute cross-tolerance to i.v. morphine? Br. J. Anaesth. 78(3), 311-313 (1997).
37. Cortinez LI, Brandes V, Munoz HR, Guerrero ME, Mur M. No clinical evidence of acute opioid tolerance after remifentanil-based anaesthesia. Br. J. Anaesth. 87(6), 866-869 (2001).
38. Collett BJ. Opioid tolerance: the clinical perspective. Br. J. Anaesth. 81(1), 58-68 (1998).
39. Foley KM. The treatment of cancer pain. N. Engl. J. Med. 313(2), 84-95 (1985).
40. Foley KM. Controversies in cancer pain. Medical perspectives. Cancer 63(11 Suppl.), 2257-2265 (1989).
41. Mercadante S, Portenoy RK. Opioid poorly-responsive cancer pain. Part 2: basic mechanisms that could shift dose response for analgesia. J. Pain Symptom Manage. 21(3), 255-264 (2001).
42. Portenoy RK, Payne D, Jacobsen P. Breakthrough pain: characteristics and impact in patients with cancer pain. Pain 81(1-2), 129-134 (1999).
43. Walker P, Watanabe S, Taube A. The Edmonton Staging System. J. Pain Symptom Manage. 12(5), 269 (1996).
44. Nekolaichuk CL, Fainsinger RL, Lawlor PG. A validation study of a pain classification system for advanced cancer patients using content experts: the Edmonton Classification System for Cancer Pain. Palliat. Med. 19(6), 466-476 (2005).
45. Wilson GR, Reisfield GM. Morphine hyperalgesia: a case report. Am. J. Hosp. Palliat. Care 20(6), 459-461 (2003).
46. Mercadante S, Ferrera P, Villari P, Arcuri E. Hyperalgesia: an emerging iatrogenic syndrome. J. Pain Symptom Manage. 26(2), 769-775 (2003).
47. Heger S, Maier C, Otter K, Helwig U, Suttorp M. Morphine induced allodynia in a child with brain tumour. BMJ 319(7210), 627-629 (1999).
48. France RD. Urban BJ, Keefe FJ. Long-term use of narcotic analgesics in chronic pain. Soc. Sci. Med. 19(12), 1379-1382 (1984).
49. Pappagallo M, Campbell JN. Chronic opioid therapy as alternative treatment for post-herpetic neuralgia. Ann. Neurol. 35(Suppl.), S54-S56 (1994),
50. Penn RD, Paice JA. Chronic intrathecal morphine for intractable pain. J. Neurosurg. 67(2), 182-186 (1987).
51. Plummer JL, Cherry DA, Cousins MJ, Gourlay GK, Onley MM, Evans KH. Long-term spinal administration of morphine in cancer and non-cancer pain: a retrospective study. Pain 44(3), 215-220 (1991).
52. Urban BJ, France RD, Steinberger EK et al. Long-term use of narcotic/antidepressant medication in the management of phantom limb pain. Pain 24(2), 191-196 (1986).
53. ZenzM, Strumpf M, Tryba M. Long-term oral opioid therapy in patients with chronic nonmalignant pain, J. Pain Symptom Manage. 7(2), 69-77 (1992).
54. Mahowald ML, Singh JA, Majeski P. Opioid use by patients in an orthopedics spine clinic. Arthritis Rheum. 52(l), 312-321 (2005).
55. Sjogren P. Jensen NH, Jensen TS. Disappearance of morphine-induced hyperalgesia after discontinuing or substituting morphine with other opioid agonists. Pain 59(2), 313-316 (1994).
56. Sjøgren P, Jonsson T, Jensen NH, Drenck NE, Jensen TS. Hyperalgesia and myoclonus in terminal cancer patients treated with continuous intravenous morphine. Pain 55(1), 93-97 (l993).
57. De Conno F, Caraceni A, Martini C, Spoldi E, Salvetti M, Ventafridda V. Hyperalgesia and myoclonus with intrathecal infusion of high-dose morphine. Pain 47(3), 337-339 (1991).
58. Lawlor P, Walker P, Bruera E, Mitchellet S. Severe opioid toxicity and somatization of psychosocial distress in a cancer patient with a background of chemical dependence. J. Pain Symptom Manage. 13(6), 356-361 (1997).
59. Parisod E, Siddall PJ, Viney M, McClelland JM, Cousins MJ. Allodynia after acute intrathecal morphine administration in a patient with neuropathic pain after spinal cord injury. Anesth. Analg. 97(1), 183-186 (2003).
60. Alford DP, Compton P, Samet JH. Acute pain management for patients receiving maintenance methadone or buprenorphine therapy. Ann. Intern. Med. 144(2), 127-134 (2006).
61. Compton P, Charuvastra VC, Kintaudi K, Ling W. Pain responses in methadone-maintained opioid abusers. J. Pain Symptom Manage. 20(4), 237-245 (2006).
62. Liebman PM, Lehofer M, Schönauer-Cejpek M et al. Pain sensitivity in former opioid addicts. Lancet 344(8928), 1031-1032 (1994).
63. Kayser V, Besson JM, Guilbaud G. Paradoxical hyperalgesic effect of exceedingly low doses of systemic morphine in an animal model of persistent pain (Freund's adjuvant-induced arthritic rats). Brain Res. 414(l), 155-157 (1987).
64. Crain SM, Shen KF. Acute thermal hyperalgesia elicited by low-dose morphine in normal mice is blocked by ultra-low-dose naltrexone. Unmasking potent opioid analgesia. Brain Res. 888(l), 75-82 (2001).
65. van der Kooy D, Nagy JI. Hyperalgesia mediated by peripheral opiate receptors in the rat. Behav. Brain Res. 17(3), 203-211 (1985).
66. Andrews HL. The effect of opiates on the pain threshold in post-addicts. J. Clin. Invest. 22(4), 511-516 (1943).
67. Kayser V, Guilbaud G. Dose-dependent analgesic and hyperalgesic effects of systemic naloxone in arthritic rats. Brain Res. 226(1-2), 433-438 (1981).
68. Levine JD, Gordon NC, Fields HL. Naloxone dose dependently produces analgesia and hyperalgesia in postoperative pain. Nature 278(5706), 740-741 (1979).
69. Blay M, Orban JC, Rami L et al. Efficacy of low-dose intrathecal morphine for postoperative analgesia after abdominal aortic surgery: a double-blind randomized study. Reg. Anesth. Pain Med. 31(2), 127-133(2006).
70. Ossipov MH, Lai J, Vanderah TW, Porreca F. Induction of pain facilitation by sustained opioid exposure: relationship to opioid antinociceptive tolerance. Life Sci. 73(6), 783-800 (2003).
71. Prommer E. Rotating methadone to other opioids: a lesson in the mechanisms of opioid tolerance and opioid-induced pain. J. Palliat. Med. 9(2), 488-493 (2006).
72. Manfredi PL, Gonzales GR, Cheville AL, Komick C, Payne R. Methadone analgesia in cancer pain patients on chronic methadone maintenance therapy. J. Pain Symptom Manage. 21(2), 169-174 (2001).
73. Mao J, Price DD, Mayer DJ. Thermal hyperalgesia in association with the development of morphine tolerance in rats: roles of excitatory amino acid receptors and protein kinase C. J. Neurosci. 14(4), 2301-2312 (1994).
74. Chen L, Huang LY. Sustained potentiation of NMDA receptor-mediated glutamate responses through activation of protein kinase C by a mu opioid. Neuron 7(2), 319-326 (1991).
75. Li N, Lundeberg T, Yu LC. Involvement of CGRP and CGRP1 receptor in nociception in the nucleus accumbens of rats. Brain Res. 901(1-2), 161-166 (2001).
76. Hiruma H, Saito A, Ichikawa T et al. Effects of substance P and calcitonin gene-related peptide on axonal transport in isolated and cultured adult mouse dorsal root ganglion neurons. Brain Res. 883(2), 184-191 (2000).
77. Huang Y, Brodda-Jansen G, Lundeberg T, Yu LC. Anti-nociceptive effects of calcitonin gene-related peptide in nucleus raphe magnus of rats: an effect attenuated by naloxone. Brain Res. 873(1), 54-59 (2000).
78. Yu LC, Weng XH, Wang JW, Lundeberg T. Involvement of calcitonin gene-related peptide and its receptor in anti-nociception in the periaqueductal grey of rats. Neurosci. Lett. 349(l), 1-4 (2003).
79. Vaughan CW, Ingram SL, Connor MA, Christie MJ. How opioids inhibit GABA-mediated neurotransmission. Nature 390(6660), 611-614 (1997).
80. Kissin I, Bright CA, Bradley EL Jr. Acute tolerance to continuously infused alfentanil: the role of cholecystokinin and N-methyl-D-aspartate-nitric oxide systems. Anesth. Analg. 91(l), 110-116 (2000).
81. Rong W, Winchester WJ, Grundy D. Spontaneous hypersensitivity in mesenteric afferent nerves of mice deficient in the sst2 subtype of somatostatin receptor. J. Physiol. 581(Pt 2), 779-786 (2007).
82. + channels formed by GIRK1 and GIRK2 subunits modulate thermal nociception and contribute to morphine analgesia. J. Neurosci. 24(l1), 2806-2812(2004).
83. Robinson TE, Kolb B. Morphine alters the structure of neurons in the nucleus accumbens and neocortex of rats. Synapse 33(2), 160-162 (1999).
84. White JM. Pleasure into pain: the consequences of long-term opioid use. Addict. Behav. 29(7), 1311-1324 (2004).
85. Ackerman WE 3rd. Effect of gender on pain perception and pharmacologic management. J. Ark. Med. Soc. 103(5), 115-116 (2006).
86. Holtman JR Jr, Wala EP Characterization of morphine-induced hyperalgesia in male and female rats. Pain 114(1-2), 62-70 (2005).
87. Koppert W, [Opioid-induced analgesia and hyperalgesia]. Schmerz 19(5), 392-394 (2005).
88. Cook CD, Nickerson MD. Nociceptive sensitivity and opioid antinociception and antihyperalgesia in Freund's adjuvant-induced arthritic male and female rats. J. Pharmacol. Exp. Ther. 313(l), 449-459 (2005).
89. Goodchild CS, Nadeson R, Cohen E. Supraspinal and spinal cord opioid receptors are responsible for antinociception following intrathecal morphine injections. Eur. J. Anaesthesiol. 21(3), 179-185 (2004).